Combined Low-Dose Pioglitazone, Flutamide, and Metformin for Women with Androgen Excess | Zendy

Lourdes Ibáñez | Zendy; Abel LópezBermejo | Zendy; Luis del Río | Zendy; Goya Enríquez | Zendy; Carme Valls | Zendy; Francis de Zegher | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combined Low-Dose Pioglitazone, Flutamide, and Metformin for Women with Androgen Excess

Author(s) -

Lourdes Ibáñez,

Abel LópezBermejo,

Luis del Río,

Goya Enríquez,

Carme Valls,

Francis de Zegher

Publication year - 2007

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2006-2684

Subject(s) - pioglitazone , flutamide , metformin , endocrinology , context (archaeology) , medicine , hyperandrogenism , antiandrogen , androgen receptor , androgen , blockade , prostate cancer , insulin , polycystic ovary , type 2 diabetes , insulin resistance , diabetes mellitus , hormone , receptor , cancer , biology , paleontology

One of the treatments for hyperinsulinemic hyperandrogenism in nonobese women is combined androgen receptor blockade (with flutamide; Flu), insulin sensitization (with metformin; Met) plus an estroprogestagen contraceptive. We tested whether adding low-dose pioglitazone (Pio; 7.5 mg/d) confers more benefit.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research